| 2011-04-21: |
Pevion's shareholders elect Jean - Paul Prieels, former Head Research GSK Vaccines, to its Board
Ittigen / Bern, Switzerland ( na Originaltextservice ) - Pevion Biotech AG today announced that Jean - Paul Prieels has joined its Board of Directors. Until January 2011, Dr. Prieels was Senior Vice President Research and Development at GlaxoSmithKline Biologicals. Jean - Paul Prieels joined GlaxoSmithKline (...) |
| 2008-04-24: |
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
Collegeville, Pennsylvania ( PRN/ots ) - - Wyeth Withdraws European Application Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it is withdrawing its application for an extension to the European Marketing Authorization for TYGACIL( R ) ( tigecycline ). This extension sought approval of TYGACIL for (...) |
| 2007-05-24: |
Workplace Burden of Depression Magnified by Co - morbid Fatigue and Anxiety, New Study Shows
San Diego ( PRN/ots ) - Depression, well known to reduce workplace productivity, causes significantly greater productivity declines when accompanied by common co - occurring conditions such as fatigue, sleep problems or anxiety, according to a large new study presented today at the American Psychiatric Association's (...) |
| 2009-09-22: |
Jane Seymour Lends Support to Recognise the Hopes and Achievements of People Living With Rheumatoid Arthritis ( RA )
Maidenhead, England ( PRN/ots ) - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening (...) |
| 2005-03-17: |
Taxol( r ) ( paclitaxel ) Approved in Europe for the Adjuvant Treatment of Node - Positive Breast Cancer
Paris ( PRN/ots ) - - New Indication Means More Patients Could Benefit From Earlier Treatment Bristol - Myers Squibb announces the approval of Taxol( r ) ( paclitaxel ) for the treatment of early stage node - positive breast cancer following standard anthracycline and cyclophosphamide ( AC ) therapy. According to the approval, (...) |
| 2005-10-26: |
Tipranavir's EU Approval Provides a New Active Drug to be Combined with FUZEON( R ) for HIV Patients Facing Resistance
Basel, Switzerland ( PRN/ots ) - Following today's European approval of Boehringer Ingelheim's boosted protease inhibitor tipranavir ( APTIVUS( R ) ), European patients now have the chance to benefit from the potent combination of the fusion inhibitor FUZEON ( enfuvirtide ) and boosted tipranavir in addition to their current treatment regimen. The (...) |
| 2010-05-25: |
NEVO( TM ) Sirolimus - Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve - Month Data
Paris, May 25, 2010 ( PRN/ots ) - At 12 months the NEVO( TM ) Sirolimus - eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus( R ) Liberte( R ) according to new data presented today from the NEVO( TM ) RES - I clinical trial. These results were (...) |
| 2008-07-03: |
Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in Cirrhotic Ascites
Turnhout, Belgium ( PRN/ots ) - Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple - dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients (...) |
| 2005-07-04: |
AstraZeneca to Start Phase III Trials With ZACTIMA ( TM ) ( ZD6474 ) - a Novel Targeted Lung Cancer Treatment
Barcelona, Spain ( PRN/ots ) - AstraZeneca ( LSE: AZN, NYSE: AZN ) announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 - now also known by its trade name, ZACTIMA ( TM ). Recruitment to Phase III studies evaluating the anti - (...) |
| 2011-03-28: |
Ocean Nutrition Canada Honours Wilmar International Limited for 2010 Most Significant Contribution to Human Health Award in the Omega - 3 Sector
Dartmouth, Nova Scotia ( PRN/ots ) - Ocean Nutrition Canada Limited ( ONC ), the world's largest Omega - 3 EPA/DHA solutions provider, and supplier of MEG - 3( R ) brand Omega - 3 EPA/DHA ( eicosapentaenoic acid/docosahexaenoic acid ) ingredients, is pleased to announce that it recently presented Wilmar International (...) |
| 2004-10-29: |
Leading Oncologists Say Up to 40 Percent of Newly Diagnosed Colon Cancer Patients Could Be Successfully Treated by Burgery and Chemotherapy
Vienna, Austria ( PRN/ots ) - - Medical experts and patients call for early diagnosis to improve chances of cure According to leading oncologists, speaking today at the European Society for Medical Oncology, findings from the MOSAIC study represent a significant step forward in providing (...)
References 1. Andre, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350( 23 ):2343 - 51 2. United European Gastroenterology Federation. Public Awareness of Colorectal Cancer in Europe, 2003 3. Bleiberg, et al. Colorectal cancer: a clinical guide to therapy. T&F STM ; 1st edition ( December 20, 2001 ) 4. Ellenhorn, et al. 'Colorectal and anal cancers' in Cancer Management, 8th ed, 2004 CMP Healthcare Media 5. Kirkwood, et al. Current cancer therapeutics ( 4th edition ), 2001 6. Summary of Product Characteristics ( SmPC ) 7. De Gramont, et al. Leucovorin and fluorouracil with or without oxaliplatin as first - line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938 - 2947
ots Originaltext: Colon Cancer Concern Im Internet recherchierbar: http://www.presseportal.de Contact: For further information contact: William Bratton, sanofi aventis, Tel + 33 - ( 0 )1 - 53 - 77 - 4167, Mob +33 - ( 0 )608 - 17 - 2943; Ian Beaumont, Colon Cancer Concern, Tel +44 - ( 0 )207 - 381 - 9711, Mob +44 - ( 0 )7966 - 522 - 962 |
| 2009-09-28: |
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott Park, Illinois ( PRN/ots ) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long - term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending capacity to accelerate promising pipeline programs - Establishes Abbott's presence in the growing global (...) |
| 2006-10-05: |
FUZEON Combined With New Investigational HIV Drug Results in Remarkably High Number of HIV Patients Achieving Undetectable Viral Load
Basel ( PRN/ots ) - - Results Unveiled at ICAAC Show That Over 90 Prozent of Treatment - Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment - experienced HIV patients who initiate therapy with FUZEON( R ) ( enfuvirtide ) (...) |
| 2006-09-12: |
Medify Solutions Limited ( Pink Sheets - MFYS ) - Forward Order Book
Gateshead, England ( PRN/ots ) - Medify Solutions Limited ( Pink Sheets - MFYS ), today received partner approval to release the current forward order book. These figures include all current and forward sales for both the UK and European operations. Medify Solutions Limited is contracted to deliver the (...) |
| 2010-02-09: |
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive (...) |
| 2009-11-16: |
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre - Menopausal Women With Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany, November 16 ( PRN/ots ) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under - Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg (...) |
| 2008-10-02: |
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Stockholm ( PRN/ots ) - Athera Biotechnologies AB and Dyax Corp. ( NASDAQ:DYAX ) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration follows the recent publication of work (...) |
| 2009-08-31: |
Abbott Launches Next - Generation XIENCE PRIME( TM ) Drug Eluting Stent in International Markets
Barcelona, Spain ( PRN/ots ) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market - Leading XIENCE V( R ) Drug Eluting Stent Abbott ( NYSE: ABT ) today announced (...) |
| 2008-10-27: |
Phase 3 Data Indicate Investigational 13 - valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
Washington ( PRN/ots ) - - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to (...) |
| 2008-05-22: |
AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
Amsterdam, The Netherlands ( PRN/ots ) - Amsterdam Molecular Therapeutics ( Euronext: AMT ), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA ( snRNA ) - based exon - skipping technology (...) |
| 2005-03-09: |
Abbott Fund, Baylor College of Medicine and the Government of Malawi to Build New Clinic for HIV - Infected Children
Lilongwe, Malawi ( PRN/ots ) - The Abbott Fund, Baylor College of Medicine and the Government of Malawi have announced they will partner in the establishment of Malawi's first center dedicated to providing care and treatment for children with HIV/AIDS. Construction of the new clinic (...) |
| 2010-04-15: |
Growing Threat From Potentially Lethal Diseases Highlighted at Meeting of Global Experts
New York, April 15, 2010 ( PRN/ots ) - As experts from around the world met in New York this week they discussed the need for greater understanding of the threat posed by ticks, fleas and sand flies. Leading scientists called on veterinarians and dog - (...) |
| 2006-04-24: |
Neuropharma Introduces in Clinical Trials its First Medicine for the Treatment of Alzheimer's
Madrid, Spain ( PRN/ots ) - - Preliminary Tests Demonstrate That the NP031112 Molecule has a Very Innovative Therapeutic Potential - Phase I Will Consist of Two Stages: in the First One the Drug Will be Administrated in Scalating Single Doses, and in the Second One, (...) |
| 2008-01-14: |
Roche Responds to Announcement of "IDEAL" Hepatitis C Study
Basel, Switzerland ( PRN/ots ) - Following an announcement from Schering - Plough, Roche today affirmed the value of PEGASYS( R ) ( peginterferon alfa - 2a ) in combination with COPEGUS( R ) ( Roche's brand of ribavirin ) as the market - leading treatment for patients with hepatitis C. Despite clear biases in the design (...) |
| 2004-12-17: |
Gefitinib ( Iressa( TM ) ) Lung Cancer ISEL Trial Shows no Overall Survival Advantage in a Highly Refractory Population
London ( PRN/ots ) - AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer ( ISEL ) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in (...)
UK freephone 0800 - 279 - 9640 US freephone 1 - 866 - 850 - 2201 Europe +44 - ( 0 )20 - 7019 - 9504 Emergency back - up +44 - ( 0 )20 - 7098 - 0713 Journalists may listen in only on the following number: +44 - ( 0 ) - 20 - 7784 - 1004 UK Toll This will be followed by a journalist teleconference at 13.15 GMT. Dial in details for this teleconference are as follows: +44 - ( 0 ) - 20 - 7098 - 0713 UK Toll +46 - ( 0 ) - 85 - 661 - 8405 Sweden Toll
ots Originaltext: AstraZeneca Im Internet recherchierbar: http://www.presseportal.de Contact: Media Enquiries: Edel McCaffrey, Tel: +44 - ( 0 ) - 207 - 304 - 5034 Steve Brown, Tel: +44 - ( 0 ) - 207 - 304 - 5033 Investor Enquiries: Mina Blair, Tel: +44 - ( 0 ) - 207 - 304 - 5084 Jonathan Hunt, Tel: +44 - ( 0 ) - 207 - 304 - 5087 |
| 2007-03-19: |
84 Percent of Psychiatrists Surveyed Rank Weight Gain or Metabolic Impact as the Most Problematic Effect of Antipsychotic Treatment( 1 )
Madrid ( PRN/ots ) - - New Survey Indicates There is Room for Improvement in Physical Health Management Strategies for People Living With Schizophrenia New data presented at the 15th European Congress of Psychiatry ( AEP ) indicates that the impact of weight gain and metabolic abnormalities (...) |
| 2006-05-23: |
New Data Shed Light on the Global Incidence of Constipation
Ingelheim, Germany ( PRN/ots ) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in (...) |
| 2008-11-14: |
SYGNIS Receives Orphan Drug Designation from the European Commission for AX200 in the treatment of Spinal Cord Injury
Heidelberg ( na Originaltextservice ) - - Second indication for AX200 given Orphan Drug status SYGNIS Pharma AG ( Frankfurt: LIO; ISIN DE0005043509; Prime Standard ), today announced that it has received Orphan Drug designation from the European Commission for AX200 in the treatment of Spinal (...) |
| 2011-01-19: |
International Society for Cellular Therapy ( ISCT ) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease
Vancouver ( PRN/ots ) - In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announces its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease ( PVD ). PVD is a condition in which (...) |
| 2008-12-04: |
European Commission Approval of New Indication for Roche's Pegasys( R ) ( peginterferon alfa - 2a ) Offers Hepatitis C Patients a Second Chance for a Cure
Basel ( PRN/ots ) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment - Experienced Patients Roche announced today that the European Commission has approved Pegasys( R ) ( peginterferon alfa - 2a ( 0 KD ) ) plus Copegus( R ) (...) |
| 2010-09-03: |
Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once - Daily HIV Treatment TMC278
Cork, Ireland ( PRN/ots ) - Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application ( MAA ) to the European Medicines Agency ( EMA ) for TMC278 ( rilpivirine, as hydrochloride ), an investigational non - nucleoside reverse transcriptase inhibitor ( NNRTI ) for the treatment of HIV. The proposed indication would make (...) |
| 2007-10-01: |
Centrally acting analgesic tapentadol - latest phase II data for the treatment of acute postoperative pain presented
Aachen ( na Originaltextservice ) - At this year's 4th World Congress of the World Institute of Pain ( WIP ), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one (...) |
| 2006-12-17: |
Long - Term Safety Data for Arimidex( TM ) ( Anastrozole ) Reinforce Patient Benefits Over Tamoxifen in Early Breast Cancer
San Antonio, Texas ( PRN/ots ) - - Safety and Tolerability Advantages With 'Arimidex' Pave the Way for New Treatment Combinations and Potential in Breast Cancer Prevention For Health Professional Press Only FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA Data presented for the first (...) |
| 2008-05-06: |
The American Psychiatric Association's Awards for Young Scientists Encourage Research Expertise in China
Washington, Dc ( PRN/ots ) - - International Reach of 'Young Minds in Psychiatry' Awards is Boosted With AstraZeneca Support For the first time, a researcher from China has received one of the American Psychiatric Association's ( APA ) prestigious "Young Minds in Psychiatry" awards, which were (...) |
| 2007-12-05: |
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
Copenhagen ( PRN/ots ) - - Attention Medical Trade Press Only - Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression and provides a further (...) |
| 2006-05-22: |
New Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany ( PRN/ots ) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25 Prozent of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international (...) |
| 2009-10-05: |
Onglyza( R ) ( saxagliptin ) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( NYSE: BMY ) and AstraZeneca ( NYSE: AZN ) ( LSE: AZN ) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once - (...) |
| 2006-01-24: |
Quintiles Signs Agreement to Join Pharma Commercialization Joint Venture in Asia Pacific
Research Triangle Park, North Carolina ( PRN/ots ) - - Quintiles to partner with Interpharma Asia Pacific and Temasek Holdings Limited - JV to have US$112 million investment fund to expand pharmaceutical sales in Asia Pacific Quintiles Transnational Corp. today announced that it (...) |
| 2006-07-27: |
PharmaMar Submits Marketing Authorization Application in Europe for Yondelis( R ) In Soft Tissue Sarcoma
Madrid ( PRN/ots ) - PharmaMar today announces the submission of a Marketing Authorization Application to the European Medicines Agency ( EMEA ) for Yondelis( R ) ( trabectedin ) as a treatment for soft tissue sarcomas ( STS ). The application is based on the results of a randomised, Phase II pivotal study (...) |
| 2009-07-27: |
European CHMP Issues Positive Opinion on Wyeth's TORISEL for Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Maidenhead, England ( PRN/ots ) - Wyeth Europa, a division of Wyeth ( NYSE:WYE ), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) recommending the approval of the mTOR ( mammalian (...) |
| 2009-04-27: |
Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that the European Commission has granted marketing authorization for CONBRIZA( TM ) ( bazedoxifene ), a selective estrogen receptor modulator ( SERM ), for the treatment of postmenopausal osteoporosis in women at increased risk of (...) |
| 2011-02-21: |
Sanofi Pasteur and International Vaccine Institute Partner Against Dengue
Lyon, France ( PRN/ots ) - Sanofi Pasteur, the vaccines division of sanofi - aventis Group , announced today that it is partnering with the International Vaccine Institute ( IVI ) to support the recently launched Dengue Vaccine Initiative ( DVI ). Sanofi Pasteur and the IVI will aim to raise (...) |
| 2006-03-20: |
Quintiles Data Management to Conduct 200th EDC Trial
Research Triangle Park, North Carolina ( PRN/ots ) - - Emerging U.S. company Aerovance Inc. studying COPD drug in U.K. Quintiles Transnational Corp. today announced that it has reached a significant milestone in data management - - the 200th clinical trial using Electronic Data Capture ( EDC ). (...) |
| 2004-10-28: |
PharmaMar's Kahalalide F, Phase II Trials for the Treatment of Severe Psoriasis
Madrid ( PRN/ots ) - PharmaMar today announced that Kahalalide F ( KF ), its marine - origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis. KF is currently undergoing Phase II clinical trials in various tumours: melanoma, non - small lung (...) |
| 2008-03-17: |
ALK - Abelló, the Makers of GRAZAX( R ), Present Successful Phase III Clinical Study Results with Children
Horsholm, Denmark ( PRN/ots ) - - Results Show Highly Significant Effect on Rhinoconjunctivitis ( Hay Fever ) and Asthma Symptoms in Children from age 5 to 16 Years - old ALK - Abelló yesterday presented successful Phase III clinical study results with GRAZAX( R ) in children at the American (...) |
| 2008-05-14: |
New Data Support Routine Childhood Vaccination With PREVENAR in Europe
Maidenhead, England ( PRN/ots ) - - PREVENAR Shown to Reduce Invasive Pneumococcal Disease in Young Children Data presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases ( ESPID ) in Graz, Austria, provide additional evidence of the public health impact of (...) |
| 2006-10-31: |
Shire Launches New Trial for First Renal Anaemia Treatment Produced in Human Cell Lines
Basingstoke, England ( PRN/ots ) - Shire today announced the start of a new Phase IIIb clinical trial to evaluate two new dosing schedules of DYNEPO( R ) ( epoetin delta ), the first commercial erythropoiesis - stimulating agent produced in a human cell line. DYNEPO is used in the treatment (...) |
| 2009-09-15: |
Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. ( NYSE: AGN ) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery and ophthalmic drug development with a goal (...) |
| 2006-07-18: |
Fosrenol( R ) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day
Basingstoke, England ( PRN/ots ) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate Binder Therapies New data show calcium - free FOSRENOL ( lanthanum carbonate ) further reduces phosphate levels in dialysis patients previously (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
